Abstract: By using the biomarker of the present invention, early diagnosis of premature ovarian insufficiency is possible, diagnosis differentiating between premature ovarian insufficiency and premature ovarian insufficiency caused by Turner syndrome is possible, and a method for screening a therapeutic agent for premature ovarian insufficiency through a change in the expression of the biomarker can be provided.

Abstract: The present invention relates to a method for evaluating radiotherapy planning. The present invention provides a method for evaluating radiotherapy planning, the method comprising the steps of: (a) acquiring a dose distribution of generated radiotherapy planning for the target volume according to the prescribed dose; (b) calculating dose gradient index (DGI) of 3-dimensional isodose levels of the acquired dose distribution, by using distances between the isodose levels; and (c) generating a differential dose gradient curve (dDGC) by plotting the calculated dose gradient index (DGI) as a function of the dose over the range of dose distributions.

Abstract: Proposed is a system and method for segmentating brain in MRI images. According to an embodiment, it is possible to overcome limitations that gray matter is estimated to be smaller than the actual size in brain segmentation performed for quantitative analysis of a brain imaged by a magnetic resonance imaging (MRI) scanner and to accurately segment brain images by distinguishing dura mater and veins around the cerebellum by removing a large amount of cranial dura mater, thereby improving accuracy of brain quantitative analysis results and fundamentally increasing diagnostic accuracy for brain lesions.

Abstract: Provided are a method for providing information about the diagnosis of a gallbladder polyp and a device for providing information about the diagnosis of a gallbladder polyp using same. The method for providing information about the diagnosis of a gallbladder polyp being implemented by a processor includes the steps of receiving an ultrasound medical image including a gallbladder part of a subject, determining the pathogenesis of a gallbladder polyp in the subject using a first assessment model configured to determine the pathogenesis of a gallbladder polyp on the basis of the ultrasound medical image, and determining characteristics of the gallbladder polyp on the basis of a second assessment model configured to classify characteristics of the gallbladder polyp when the gallbladder polyp is determined in the ultrasound medical image.

Abstract: The present invention relates to a method for screening drug candidates for treating a disease using the interaction between calcium and phosphatidylinositol phosphate. Particularly in the present invention, it was confirmed that the concentration of calcium was increased in the obesity induced insulin resistance animal model and the increased calcium concentration inhibited the migration of Akt protein containing PH domain and the signal transduction, while the protein containing C2 domain was able to migrate to the cell membrane by binding to calcium/PIP complex even under the condition of high calcium concentration. Therefore, the investigation of the interaction between calcium and PIP can be a useful method for screening of drug candidates for treating metabolic disease, cancer or hypertension.

Abstract: The present invention relates to a method for predicting the possibility of immunotherapy for a colorectal cancer patient. Specifically, by using a discriminant of a multiple linear model for determining the applicability of anticancer immunotherapy to obese colorectal cancer patients of the present invention, the patients are classified into two patient groups according to the type of gene mutation, and a patient group with a high immune signature is selected as a group to which immunotherapy can be applied such that it is possible to provide the benefit of providing a new treatment opportunity to obese colorectal cancer patients who have not benefited from the anticancer immunotherapy.

Abstract: The present invention relates to a method for prevention or treatment of metabolic disease, administering a composition containing bone morphogenetic protein 10 (BMP10) as an active ingredient, in which brown fat differentiation was promoted in the cells of BMP10-treated mouse embryonic mesenchymal cell line C3H10T1/T2, increased browning effects of stromal vascular fraction adipose stem cells isolated from subcutaneous adipose tissue was confirmed, and weight loss, improved insulin resistance, and changes in blood lipid levels were confirmed in a high-fat-diet-induced obese animal model. Therefore, the composition containing BMP10 as an active ingredient can be provided as a drug for the prevention or treatment of metabolic diseases, including obesity, diabetes, and dyslipidemia.

Abstract: There is provided a method for determining dementia risk factors by a server using deep learning. In this instance, the method for determining dementia risk factors includes acquiring biometric information from each subject corresponding to a first control group through a wearable device, acquiring measurement information for each subject corresponding to the first control group, deriving a first dementia risk factor based on the biometric information and the measurement information for each subject, and deriving a second dementia risk factor related to the first dementia risk factor via deep learning performed based on the biometric information related to the first dementia risk factor and control group information.

Abstract: The present invention relates to a pharmaceutical composition comprising a STT compound as an active ingredient for the prevention or treatment of Parkinson's disease. STT showed neuroprotective effect and apoptosis recovery effect in the Parkinson's disease cell model, restored the reduced motility in the MPTP animal model, and was shown to significantly protect dopamine cells, so it can be used for the prevention and treatment of Parkinson's disease.

Abstract: The present invention relates to a composition comprising the UNE-L domain of leucyl-tRNA synthetase as an effective ingredient for increasing muscle. More particularly, the UNE-L domain of LRS according to the present invention, which is a region that controls activity of Vps34, activates mTORC1 involved in protein synthesis and increases myocyte differentiation and muscle fiber regeneration, thus finding useful application in muscle augmentation.

Abstract: The present invention relates to a parathyroid hormone derivative in a dimeric form of a parathyroid hormone fragment and a pharmaceutical composition for the prevention or treatment of bone diseases comprising same. When administered to an animal model, the parathyroid hormone derivative in the dimeric form of the parathyroid hormone according to the present invention significantly increases bone density and enhances osteogenesis and thus can be effectively used for the treatment and prevention of bone diseases.

Abstract: A biological classification device and a method for Alzheimer's disease using a brain image are disclosed. The biological classification device includes an image receiving unit which receives a plurality of images obtained by capturing images of a brain of a subject; an image processing unit which acquires neurodegeneration feature related to the brain of the subject and standardized uptake value ratio (SUVR) information from the plurality of images; an image analysis unit which performs first determination of a presence or absence of cranial nerve abnormality based on the neurodegeneration feature(s) and second determination and third determination of a presence or absence of abnormality of beta amyloid protein and tau protein, respectively, based on the SUVR information; and a classifying unit which performs biological classification of the subject related to Alzheimer's disease using the first, the second, and the third determinations together.

Abstract: The present invention relates to a novel 4-carbonylamino-4-phenylpyrimidine compound or a pharmaceutically acceptable salt thereof. Specifically, the present invention relates to a novel 4-carbonylamino-4-phenylpyrimidine compound or a pharmaceutically acceptable salt thereof, which exhibits GDH activity and as such, is effective for prevention or treatment of obesity, diabetes, or fatty liver.

Abstract: A variable PET apparatus allows structural changes of detector modules in transversal and longitudinal directions to correspond to various imaging purposes and a cross-sectional diameter of a subject while maintaining an arrangement of the detector modules to be close to a true circle. The variable PET apparatus includes: a gantry having an opening on a longitudinal axis; and detector modules supported on the gantry and arranged a predetermined distance apart from each other such that a detection ring is configured with a diameter in a circumferential direction, wherein the gantry is driven by a gantry drive member, and the detector modules are driven by a detector module drive member. According to the present invention, structural changes of the detector modules in the PET apparatus is possible to correspond to a cross-sectional diameter of a subject without additional devices, thereby improving the spatial resolution and sensitivity.

Abstract: The present invention provides a digestive organ endoscope system which allows a user to perceive whether or not the tip of an endoscope instrument inserted along a channel approaches the tip of an endoscope channel portion within a certain distance, thereby being capable of quickly inserting the endoscope instrument up to a position close to the tip of the endoscope channel portion, and thus, it is possible to reduce a procedure time and to prevent a digestive organ from being damaged due to instantaneous protrusion of the tip of the endoscope instrument occurring when the endoscope instrument is quickly inserted.

Abstract: The present invention relates to a novel spiroquinone derivative compound, a production method thereof, and a pharmaceutical composition for preventing or treating neurological disorders which contains the compound as an active ingredient.

Abstract: Disclosed is a multi-axially variable detection module of a PET apparatus, the detection module including: a gantry having a through-hole extending from a side to an opposite side of the gantry; a detection module in which a plurality of detectors for detecting gamma rays emitted from a subject are arranged annularly along an inner circumference of the gantry; and a driving means for moving the plurality of detectors constituting the detection module in a radial direction of the detection module, wherein each of the plurality of detectors is rotatable in a longitudinal direction of the detection module to vary a length thereof in the longitudinal direction, and each of the plurality of detectors include multiple detector elements which are engaged with each other in a hinged manner in a transverse direction (circumferential direction) of the detection module to form a flat or an arc shape.

Abstract: The present invention relates to a pharmaceutical composition comprising a STT compound as an active ingredient for the prevention or treatment of Parkinson's disease. STT showed neuroprotective effect and apoptosis recovery effect in the Parkinson's disease cell model, restored the reduced motility in the MPTP animal model, and was shown to significantly protect dopamine cells, so it can be used for the prevention and treatment of Parkinson's disease.

Abstract: The present invention relates to a data analysis method and system for disease diagnosis aid, and more specifically, to a technique and system capable of providing analysis results through integrated analysis of clinical, MRI images, and genotypic data to aid in disease diagnosis. The method includes receiving medical data of a subject; selecting disease-related data using the medical data; and calculating the disease probability according to the selected disease-related data. The medical data provides a configuration including clinical records, genetic and genetic variants, and MRI.

Abstract: The present invention relates to a method for detecting apoptosis using a phosphatidylinositol phosphate-binding material, a method for screening anticancer agents, a method for screening apoptosis-inhibiting materials, and a method for inhibiting phagocytosis.